Title

Benchmarking saliency methods for chest X-ray interpretation

Authors

Adriel Saporta MS MBA[1*], Xiaotong Gui MS[2*], Ashwin Agrawal MS[2*], Anuj Pareek MD

PhD[3], Steven QH Truong MBA[4], Chanh DT Nguyen PhD[4,5], Van-Doan Ngo MD[6], Jayne

Seekins DO[7], Francis G. Blankenberg MD[7], Andrew Y. Ng PhD[2], Matthew P. Lungren

MD MPH[3], Pranav Rajpurkar PhD[8]

Affiliations

[1]Department of Computer Science, New York University, 251 Mercer Street, New York,

NY 10012, USA

[2]Department of Computer Science, Stanford University, 353 Jane Stanford Way,

Stanford CA 94305, USA

[3]Stanford Center for Artificial Intelligence in Medicine and Imaging, 1701 Page Mill

Road, Palo Alto, CA 94304, USA

[4]VinBrain, 7 Bang Lang 1 Street, Vinhomes, Viet Hung Ward, Ha Noi 100000, Vietnam

[5]VinUniversity, Vinhomes Ocean Park, Gia Lam District, Ha Noi 100000, Vietnam

[6]Vinmec International Hospital, 458 Minh Khai, Vinh Tuy Ward, Hai Ba Trung District,

Ha Noi 100000, Vietnam

[7]Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive,

Stanford, CA 94305, USA

[8]Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street,

Suite 514, Boston, MA 02115, USA

[*]These authors contributed equally: Adriel Saporta, Xiaotong Gui, Ashwin Agrawal

Corresponding author: Pranav Rajpurkar, PhD (pranav_rajpurkar@hms.harvard.edu)

Current word count: 4501

Abstract

Saliency methods, which "explain" deep neural networks by producing heat maps that highlight the areas of the medical image that influence model prediction, are often presented to clinicians as an aid in diagnostic decision-making. Although many saliency methods have been proposed for medical imaging interpretation, rigorous investigation of the accuracy and reliability of these strategies is necessary before they are integrated into the clinical setting. In this work, we quantitatively evaluate seven saliency methods—including Grad-CAM, Grad-CAM++, and Integrated Gradients—across multiple neural network architectures using two evaluation metrics. We establish the first human benchmark for chest X-ray segmentation in a multilabel classification set up, and examine under what clinical conditions saliency maps might be more prone to failure in localizing important pathologies compared to a human expert benchmark. We find that (i) while Grad-CAM generally localized pathologies better than the other evaluated saliency methods, all seven performed significantly worse compared with the human benchmark; (ii) the gap in localization performance between Grad-CAM and the human benchmark was largest for pathologies that were smaller in size and had shapes that were more complex; (iii) model confidence was positively correlated with Grad-CAM localization performance. While it is difficult to know whether poor localization performance is attributable to the model or to the saliency method, our work demonstrates that several important limitations of saliency methods must be addressed before we can rely on them for deep learning explainability in medical imaging.

Introduction

Deep learning has enabled automated medical imaging interpretation at the level of

practicing experts in some settings[1–3]. While the potential benefits of automated

diagnostic models are numerous, lack of model interpretability in the use of "black-box"

deep neural networks (DNNs) represents a major barrier to clinical trust and adoption[4–

6]. In fact, it has been argued that the European Union's recently adopted General Data

Protection Regulation (GDPR) affirms an individual's right to an explanation in the

context of automated decision-making[7]. Although the importance of DNN interpretability

is widely acknowledged and many techniques have been proposed, little emphasis has

been placed on how best to quantitatively evaluate these explainability methods[8].

One type of DNN interpretation strategy widely used in the context of medical imaging is

based on saliency (or pixel-attribution) methods[9–12]. Saliency methods produce heat

maps highlighting the areas of the medical image that most influenced the DNN's

prediction. Since saliency methods provide post-hoc interpretability of models that are

never exposed to bounding box annotations or pixel-level segmentations during training,

they are particularly useful in the context of medical imaging where ground-truth

segmentations can be especially time-consuming and expensive to obtain. The heat

maps help to visualize whether a DNN is concentrating on the same regions of a

medical image that a human expert would focus on, rather than concentrating on a

clinically irrelevant part of the medical image or even on confounders in the image[13–15].

Saliency methods have been widely used for a variety of medical imaging tasks and

modalities including, but not limited to, visualizing the performance of a convolutional

neural network (CNN) in predicting (1) myocardial infarction[16] and hypoglycemia[17] from

electrocardiograms, (2) visual impairment[18], refractive error[19], and anaemia[20] from

retinal photographs, (3) long-term mortality[21] and tuberculosis[22] from chest X-ray (CXR)

images, and (4) appendicitis[23] and pulmonary embolism[24] on computed tomography

scans. However, recent work has shown that saliency methods used to validate model

predictions can be misleading in some cases and may lead to increased bias and loss

of user trust in high-stakes contexts such as healthcare[25–28]. Therefore, a rigorous

investigation of the accuracy and reliability of these strategies is necessary before they

are integrated into the clinical setting[29].

In this work, we perform a systematic evaluation of seven common saliency methods in

medical imaging (Grad-CAM[30], Grad-CAM++[31], Integrated Gradients[32], Eigen-CAM[41],

DeepLIFT[42], Layer-Wise Relevance Propagation[43], and Occlusion[44]) using three

common CNN architectures (DenseNet121[33], ResNet152[34], Inception-v4[35]). In doing so,

we establish the first human benchmark in CXR segmentation by collecting radiologist

segmentations for 10 pathologies using CheXpert, a large publicly available CXR

dataset[36]. To compare saliency method segmentations with expert segmentations, we

use two metrics to capture localization accuracy: (1) *mean Intersection over Union*, a

metric that measures the overlap between the saliency method segmentation and the

expert segmentation, and (2) *hit rate*, a less strict metric than mIoU that does not

require the saliency method to locate the full extent of a pathology. We find that (1)

while Grad-CAM generally localizes pathologies more accurately than the other

evaluated saliency methods, all seven perform significantly worse compared with a

human radiologist benchmark (although it is difficult to know whether poor localization

performance is attributable to the model or to the saliency method); (2) the gap in

localization performance between Grad-CAM and the human benchmark is largest for

pathologies that are smaller in size and have shapes that are more complex; (3) model

confidence is positively correlated with Grad-CAM localization performance. We publicly

release a development dataset of expert segmentations, which we call CheXlocalize, to

facilitate further research in DNN explainability for medical imaging.

Results

Framework for evaluating saliency methods

Seven methods were evaluated—Grad-CAM, Grad-CAM++, Integrated Gradients,

Eigen-CAM, DeepLIFT, Layer-Wise Relevance Propagation (LRP), and Occlusion—in a

multi-label classification setup on the CheXpert dataset (Fig. 1a). We ran experiments

using three CNN architectures previously used on CheXpert: DenseNet121,

ResNet152, and Inception-v4. For each combination of saliency method and model

architecture, we trained and evaluated an ensemble of 30 CNNs (see Methods for

ensembling details). We then passed each of the CXRs in the dataset's holdout test set

into the trained ensemble model to obtain image-level predictions for the following 10

pathologies: Airspace Opacity, Atelectasis, Cardiomegaly, Consolidation, Edema,

Enlarged Cardiomediastinum, Lung Lesion, Pleural Effusion, Pneumothorax, and

Support Devices. Of the 14 observations labeled in the CheXpert dataset, Fracture and

Pleural Other were not included in our analysis because they had low prevalence in our

test set (fewer than 10 examples); Pneumonia was not included because it is a clinical

(as opposed to a radiological) diagnosis; and No Finding was not included because it is

not applicable to evaluating localization performance. For each CXR, we used the

saliency method to generate heat maps, one for each of the 10 pathologies, and then

applied a threshold to each heat map to produce binary segmentations (top row, Fig.

1a). Thresholding is determined per pathology using Otsu's method[37], which iteratively

searches for a threshold value that maximizes inter-class pixel intensity variance. We

also conducted a second thresholding scheme in which we iteratively search for a

threshold value that maximizes per pathology mIoU on the validation set. There are no

statistically significant differences between the two thresholding schemes when

compared against the human benchmark (see Extended Data Fig. 1). Additionally, to

calculate the hit rate evaluation metric (described below), we extracted the pixel in the

saliency method heat map with the largest value as the single most representative point

on the CXR for that pathology.

We obtained two independent sets of pixel-level CXR segmentations on the holdout test

set: ground-truth segmentations drawn by two board-certified radiologists (middle row,

Fig. 1a) and human benchmark segmentations drawn by a separate group of three

board-certified radiologists (bottom row, Fig. 1a). The human benchmark segmentations

and the saliency method segmentations were compared with the ground-truth

segmentations to establish the human benchmark localization performance and the

saliency method localization performance, respectively. Additionally, for the hit rate

evaluation metric, the radiologists who drew the benchmark segmentations were also

asked to locate a single point on the CXR that was most representative of the pathology

at hand (see Supplementary Figs. S1 through S11 for detailed instructions given to the

radiologists). Note that the human benchmark localization performance demonstrates

interrater variability, and we use it as a reference when evaluating saliency method

pipelines.

We used two evaluation metrics to compare segmentations (Fig. 1b). Our primary

metric, *mean Intersection over Union* (mIoU), measures how much, on average, either

the saliency method or benchmark segmentations overlapped with the ground-truth

segmentations. Our secondary metric, *hit rate*, is a less strict metric that does not

require the saliency method or benchmark annotators to locate the full extent of a

pathology. Hit rate is based on the pointing game setup[38], in which credit is given if the

most representative point identified by the saliency method or the benchmark

annotators lies within the ground-truth segmentation. A "hit" indicates that the correct

region of the CXR was located regardless of the exact bounds of the binary

segmentations. Localization performance is then calculated as the hit rate across the

dataset[39]. We report the mean of these metrics (mIoU and hit rate) over 1,000 bootstrap

replicates on the test set, along with the 95% confidence intervals using the 2.5[th] and

97.5[th] percentiles of the empirical distribution[40]. In addition to mIoU, we report the test

set precision, recall/sensitivity, and specificity values of the saliency method pipeline

and the human benchmark segmentations to measure segmentation overlap (Extended

Data Fig. 2).

IoU: 0.078 | hit
Pleural Effusion

IoU: 0.682 | miss
Enlarged Cardiomediastinum

Fig. 1 | Framework for evaluating saliency methods. a, Top row left: a CXR image from the holdout test set is passed into an ensemble CNN trained only on CXR images and their corresponding pathology task labels. Saliency method is used to generate 10 heat maps for the example CXR, one for each task. The pixel in the heat map with the largest value is determined to be the single most representative point on the CXR for that pathology. There are three pathologies present in this CXR (Airspace Opacity, Pleural Effusion, and Support Devices). Top row right: a threshold is applied to the heat maps to produce binary segmentations for each present pathology. Middle row: Two board-certified radiologists were asked to segment the pathologies that were present in the CXR as determined by the dataset's ground-truth labels. Saliency method pipeline annotations are compared to these ground-truth annotations to determine "saliency method pipeline localization performance". Bottom row: Three board-certified radiologists (separate from those in middle row) were also asked to segment the pathologies that were present in the CXR as determined by the dataset's ground-truth labels. In addition, these radiologists were asked to locate the single point on the CXR that was most

representative of each present pathology. These benchmark annotations are compared to the
ground-truth annotations to determine "human benchmark localization performance". **b**, Left:
CXR with ground-truth and saliency method annotations for Pleural Effusion. The
segmentations have a low overlap (IoU is 0.078), but pointing game is a "hit" since the saliency
method's most representative point is inside of the ground-truth segmentation. Right, CXR
with ground-truth and human benchmark annotations for Enlarged Cardiomediastinum. The
segmentations have a high overlap (IoU is 0.682), but pointing game is a "miss" since saliency
method's most representative point is outside of the ground-truth segmentation.
188

Evaluating localization performance

In order to compare the localization performance of the saliency methods with the

human benchmark, we first used Grad-CAM, Grad-CAM++, and Integrated Gradients to

run eighteen experiments, one for each combination of saliency method (Grad-CAM,

Grad-CAM++, or Integrated Gradients) and CNN architecture (DenseNet121,

ResNet152, or Inception-v4) using one of the two evaluation metrics (mIoU or hit rate)

(see Extended Data Fig. 3). We also ran experiments to evaluate the localization

performances of DenseNet121 with Eigen-CAM, DeepLIFT, LRP, and Occlusion. We

found that Grad-CAM with DenseNet121 generally demonstrated better localization

performance across pathologies and evaluation metrics than the other combinations of

saliency method and architecture. Accordingly, we compared Grad-CAM with

DenseNet121 ("saliency method pipeline") with the human benchmark using both mIoU

and hit rate. See Table 1 for localization performance on the test set of all seven

saliency methods using DenseNet121. The localization performance for each pathology

is reported on the true positive slice of the dataset (for mIoU, the true positive slice

contains CXRs with both saliency method/human benchmark segmentations and also

ground-truth segmentations; for hit rate, the true positive slice contains CXRs with both

the most representative point identified by the saliency method/human benchmark and

also the ground-truth segmentations). Localization performance was calculated this way

so that saliency methods were not penalized by DNN classification error: while the

benchmark radiologists were provided with ground-truth labels when annotating the

dataset, saliency method segmentations were created based on labels predicted by the

model. (See Extended Data Fig. 4 for saliency method pipeline test set localization

performance on the full dataset using mIoU.)

Table 1 | Test set localization performance of saliency methods using DenseNet121

Pathology	Grad-CAM	Grad-CAM++	Integrated Gradients	Eigen-CAM	DeepLIFT	LRP	Occlusion
mIoU							
Airspace Opacity	0.248	0.234	0.123	0.293	0.111	0.112	0.242
Atelectasis	0.254	0.245	0.116	0.267	0.126	0.109	0.250
Cardiomegaly	0.452	0.346	0.160	0.379	0.167	0.150	0.312
Consolidation	0.408	0.296	0.177	0.332	0.088	0.099	0.212
Edema	0.362	0.388	0.073	0.370	0.059	0.047	0.347
Enlarged Cardiom.	0.379	0.400	0.154	0.372	0.109	0.117	0.363
Lung Lesion	0.101	0.089	0.107	0.089	0.072	0.088	0.087
Pleural Effusion	0.235	0.195	0.088	0.249	0.090	0.082	0.215
Pneumothorax	0.213	0.216	0.077	0.218	0.084	0.066	0.214
Support Devices	0.163	0.133	0.099	0.116	0.086	0.052	0.126
Hit rate							
Airspace Opacity	0.498	0.558	0.606	0.566	0.528	0.566	0.367
Atelectasis	0.501	0.621	0.520	0.530	0.415	0.468	0.343
Cardiomegaly	0.903	0.732	0.697	0.709	0.610	0.644	0.515
Consolidation	0.738	0.708	0.624	0.626	0.571	0.283	0.338
Edema	0.746	0.781	0.300	0.758	0.468	0.156	0.469
Enlarged Cardiom.	0.818	0.630	0.704	0.612	0.469	0.594	0.767
Lung Lesion	0.290	0.290	0.423	0.146	0.497	0.356	0.072
Pleural Effusion	0.507	0.347	0.332	0.439	0.408	0.283	0.291
Pneumothorax	0.392	0.489	0.801	0.195	0.801	0.697	0.297
Support Devices	0.355	0.364	0.491	0.216	0.598	0.264	0.189

We found that the saliency method pipeline demonstrated significantly worse

localization performance on the test set when compared with the human benchmark

using both mIoU (Fig. 2a) and hit rate (Fig. 2b) as an evaluation metric, regardless of

model classification AUROC. For five of the 10 pathologies, the saliency method

pipeline had a significantly lower mIoU than the human benchmark. For example, the

saliency method pipeline had one of the highest AUROC scores of the 10 pathologies

for Support Devices (0.969), but had among the worst localization performance for

Support Devices when using both mIoU (0.163 [95% CI 0.154, 0.172]) and hit rate

(0.355 [95% CI 0.303, 0.408]) as evaluation metrics. On two pathologies (Atelectasis

and Consolidation) the saliency method pipeline significantly outperformed the human

benchmark. On average, across all 10 pathologies, mIoU saliency method pipeline

performance was 24.0% [95% CI 18.2%, 29.6%] worse than the human benchmark,

with Lung Lesion displaying the largest gap in performance (76.2% [95% CI 59.1%,

87.5%] worse than the human benchmark) (Extended Data Fig. 5). Consolidation was

the pathology on which the mIoU saliency method pipeline performance exceeded the

human benchmark the most, by 128.1%. For seven of the 10 pathologies, the saliency

method pipeline had a significantly lower hit rate than the human benchmark. On

average, hit rate saliency method pipeline performance was 29.4% [95% CI 23.1%,

35.5%] worse than the human benchmark (Extended Data Fig. 6), with Lung Lesion

again displaying the largest gap in performance (65.9% [95% CI 35.3%, 91.7%] worse

than the human benchmark). The hit rate saliency method pipeline did not significantly

outperform the human benchmark on any of the 10 pathologies; for the remaining three

of the 10 pathologies, the hit rate performance differences between the saliency method

pipeline and the human benchmark were not statistically significant. Therefore, while the

saliency method pipeline significantly underperformed the human benchmark regardless

of evaluation metric used, the average performance gap was larger when using hit rate

as an evaluation metric than when using mIoU as an evaluation metric.

We compared saliency method pipeline localization performance using an ensemble

model to localization performance using the top performing single checkpoint for each

pathology. We found that on the test set the single model has worse localization

performance than the ensemble model for all pathologies when using mIoU and for six

of the 10 pathologies when using hit rate (see Extended Data Fig. 7).

Fig. 2 | Evaluating localization performance. a, performances on the test set using mIoU. **b**, Comparing saliency method pipeline and human benchmark localization performances on the test set using hit rate. For both **a** and **b**, pathologies, along with their DenseNet121 AUROCs, are sorted on the x-axis first by statistical significance of percentage decrease from human benchmark mIoU/hit rate to saliency method pipeline mIoU/hit rate (high to low), and then by percentage decrease from human benchmark mIoU/hit rate to saliency method pipeline mIoU/hit rate (high to low).

Characterizing underperformance of saliency method pipeline

In order to better understand the underperformance of the saliency method pipeline

localization, we first conducted a qualitative analysis with a radiologist by visually

inspecting both the segmentations produced by the saliency method pipeline (Grad-

CAM with DenseNet121) and the human benchmark segmentations. We found that, in

general, saliency method segmentations fail to capture the geometric nuances of a

given pathology, and instead produce coarse, low-resolution heat maps. Specifically,

our qualitative analysis found that the performance of the saliency method was

associated with three pathological characteristics (Fig. 3a): (1) *number of instances*:

when a pathology had multiple instances on a CXR, the saliency method segmentation

often highlighted one large confluent area, instead of highlighting each distinct instance

of the pathology separately; (2) *size*: saliency method segmentations tended to be

significantly larger than human expert segmentations, often failing to respect clear

anatomical boundaries; (3) *shape complexity*: the saliency method segmentations for

pathologies with complex shapes frequently included significant portions of the CXR

where the pathology is not present.

Informed by our qualitative analysis and previous work in histology[45], we defined four

geometric features for our quantitative analysis (Fig. 3b): (1) *number of instances* (for

example, bilateral Pleural Effusion would have two instances, whereas there is only one

instance for Cardiomegaly), (2) *size* (pathology area with respect to the area of the

whole CXR), (3) *elongation* and (4) *irrectangularity* (the last two features measure the

complexity of the pathology shape and were calculated by fitting a rectangle of minimum

area enclosing the binary mask). See Extended Data Fig. 8 for the test set distribution of the four pathological characteristics across all 10 pathologies.

For each evaluation metric, we ran 8 simple linear regressions: four with the evaluation metric (IoU or hit/miss) of the saliency method pipeline (Grad-CAM with DenseNet121) as the dependent variable (to understand the relationship between the geometric features of a pathology and saliency method localization performance), and four with the difference between the evaluation metrics of the saliency method pipeline and the human benchmark as the dependent variable (to understand the relationship between the geometric features of a pathology and the gap in localization performance between the saliency method pipeline and the human benchmark). Each regression used one of the four geometric features as a single independent variable, and only the true positive slice was included in each regression. Each feature was normalized using min-max normalization and the regression coefficient can be interpreted as the effect of that geometric feature on the evaluation metric at hand. See Table 2 for coefficients from the regressions using both evaluation metrics on the test set, where we also report the 95% confidence interval and the Bonferroni corrected p-values based on Student's t-distribution.

Fig. 3 | Characterizing underperformance of saliency method pipeline. a, Example CXRs that highlight the three pathological characteristics identified by our qualitative analysis: (1) Left, number of instances; (2) Middle, size; and (3) Right, shape complexity. **b,** Example CXRs with the four geometric features used in our quantitative analysis: (1) Top row left, number of instances; (2) Top row right, size = area of segmentation/area of CXR; (3) Bottom row left, elongation; and (4) Bottom row right, irrectangularity. Elongation and irrectangularity were calculated by fitting a rectangle of minimum area enclosing the binary mask (as indicated by the yellow rectangles). Elongation = maxAxis/minAxis. Irrectangularity = 1 - (area of segmentation/area of enclosing rectangle).

Our statistical analysis showed that as the size of a pathology increased, IoU saliency

method localization performance improved (0.566 [95% CI 0.526, 0.606]). We also

found that as elongation and irrectangularity increased, IoU saliency method localization

performance worsened (elongation: -0.425 [95% CI -0.497, -0.354], irrectangularity: -

0.256 [95% CI -0.292, -0.219]). We observed that the effects of these three geometric

features were similar for hit/miss saliency method localization performance in terms of

levels of statistical significance and direction of the effects. However, there was no

evidence that the number of instances of a pathology had a significant effect on either

IoU (-0.115 [95% CI -0.220, -0.010]) or hit/miss (-0.051 [95% CI -0.346, 0.244]) saliency

method localization. Therefore, regardless of evaluation metric, saliency method

localization performance suffered in the presence of pathologies that were small in size

and complex in shape.

We found that these same three pathological characteristics—size, elongation, and

irrectangularity—characterized the *gap* in IoU localization performance between

saliency method and human benchmark. We observed that the *gap* in hit/miss

localization performance was significantly characterized by all four geometric features

(number of instances, size, elongation, and irrectangularity).

Table 2 | Coefficients from regressions on geometric features of pathologies

Geometric feature (independent variable)	Coefficient using saliency method localization (dependent variable)	Coefficient using localization difference (human benchmark - saliency method) (dependent variable)
IoU		
Number of instances	-0.115 (-0.220, -0.010)	-0.072 (-0.237, 0.094)
Size	0.566 (0.526, 0.606) ***	-0.154 (-0.231, -0.076) ***
Elongation	-0.425 (-0.497, -0.354) ***	0.476 (0.362, 0.589) ***
Irrectangularity	-0.256 (-0.292 -0.219) ***	0.307 (0.249, 0.366) ***
Hit/Miss		
Number of instances	-0.051 (-0.346, 0.244)	0.470 (0.114, 0.825) *
Size	1.269 (1.146, 1.391) ***	-0.944 (-1.104, -0.785) ***
Elongation	-0.849 (-1.053, -0.646) ***	1.110 (0.865, 1.354) ***
Irrectangularity	-0.519 (-0.624, -0.415) ***	0.689 (0.564, 0.815) ***

* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001

Effect of model confidence on localization performance

We also conducted statistical analyses to determine whether there was any correlation between the model's confidence in its prediction and saliency method pipeline test set localization performance (Table 3). We first ran a simple regression for each pathology using the model's probability output as the single independent variable and using the saliency method IoU as the dependent variable. We then performed a simple regression that uses the same approach as above, but that includes all 10 pathologies. For each of the 11 regressions, we used the full dataset since the analysis of false positives and false negatives was also of interest. In addition to the linear regression coefficients, we also computed the Spearman correlation coefficients to capture any potential non-linear associations.

We found that for all pathologies, model confidence was positively correlated with IoU

saliency method pipeline performance. The p-values for all coefficients were below

0.001 except for the coefficients for Pneumothorax (n=11) and Lung Lesion (n=50), the

two pathologies for which we had the fewest positive examples. Of all the pathologies,

model confidence for positive predictions of Enlarged Cardiomediastinum had the

largest linear regression coefficient with IoU saliency method pipeline performance

(1.974, p-value<0.001). Model confidence for positive predictions of Pneumothorax had

the largest Spearman correlation coefficient with IoU saliency method pipeline

performance (0.734, p-value<0.05), followed by Pleural Effusion (0.690, p-value<0.001).

Combining all pathologies (n=2365), the linear regression coefficient was 0.109 (95% CI

[0.083, 0.135]), and the Spearman correlation coefficient was 0.285 (95% CI [0.248,

0.322]).

We also performed analogous experiments using hit/miss as the dependent variable on

the true positive slice of the test set (CXRs with both the most representative point

identified by the saliency method/human benchmark and also the ground-truth

segmentations) (Extended Data Fig. 9). Since every heat map contains a maximally

activated point (the pixel with the highest value) regardless of model probability output,

using the full dataset has limited value since false positives are due to metric set up and

are not associated with model probability. We found that model confidence was

positively correlated with hit/miss saliency method pipeline performance for four out of

10 pathologies.

Table 3 | IoU: Coefficients from regressions on model assurance

Pathology	CXRs including all positives and false negatives (n)	Linear regression coefficient	Spearman correlation coefficient
Airspace Opacity	381	0.714 (0.601, 0.826) ***	0.577 (0.506, 0.641) ***
Atelectasis	296	0.489 (0.333, 0.645) ***	0.348 (0.244, 0.444) ***
Cardiomegaly	229	0.679 (0.535, 0.823) ***	0.592 (0.501, 0.670) ***
Consolidation	120	1.155 (0.674, 1.635) ***	0.384 (0.220, 0.527) ***
Edema	124	0.642 (0.459, 0.826) ***	0.548 (0.411, 0.660) ***
Enlarged Cardiomediastinum	668	1.974 (1.608, 2.340) ***	0.428 (0.364, 0.488) ***
Lung Lesion	50	0.218 (0.088, 0.349) **	0.509 (0.268, 0.689) ***
Pleural Effusion	159	0.632 (0.489, 0.776) ***	0.690 (0.599, 0.764) ***
Pneumothorax	11	0.446 (0.108, 0.783) *	0.734 (0.240, 0.926) *
Support Devices	327	0.211 (0.172, 0.250) ***	0.468 (0.378, 0.548) ***
All pathologies	2365	0.109 (0.083, 0.135) ***	0.285 (0.248, 0.322) ***

* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001

Discussion

The purpose of this work was to evaluate the performance of some of the most used

saliency methods for deep learning explainability using a variety of model architectures.

We establish the first human benchmark for CXR segmentation in a multilabel

classification setup and demonstrate that saliency maps are consistently worse than

expert radiologists regardless of model classification AUROC. We use qualitative and

quantitative analyses to establish that saliency method localization performance is most

inferior to expert localization performance when a pathology is smaller in size or has

shapes that are more complex, suggesting that deep learning explainability as a clinical

interface may be less reliable and less useful when used for pathologies with those

characteristics. We also show that model assurance is positively correlated with

saliency method localization performance, which could indicate that saliency methods

are safer to use as a decision aid to clinicians when the model has made a positive

prediction with high confidence.

Because ground-truth segmentations for medical imaging are time-consuming and

expensive to obtain, the current norm in medical imaging—both in research and in

industry—is to use classification models on which saliency methods are applied post-

hoc for localization, highlighting the need for investigations into the reliability of these

methods in clinical settings[46,47]. There are public CXR datasets containing image-level

labels annotated by expert radiologists (e.g., the CheXpert validation set), multilabel

bounding box annotations (e.g., ChestX-ray8[48] and VinDr-CXR[49]), and segmentations

for a single pathology (e.g., SIIM-ACR Pneumothorax Segmentation[50]). To our

knowledge, however, there are no other publicly available CXR datasets with multilabel

pixel-level expert segmentations. By publicly releasing a development dataset,

CheXlocalize, of 234 images with 643 expert segmentations, we hope to encourage the

further development of saliency methods and other explainability techniques for medical

imaging.

Our work has several potential implications for human-AI collaboration in the context of

medical decision-making. Heat maps generated using saliency methods are advocated

as clinical decision support in the hope that they not only improve clinical decision-

making, but also encourage clinicians to trust model predictions[51-53]. Many of the large

CXR vendors[54–56] use localization methods to provide pathology visualization in their

computer-aided detection (CAD) products. In addition to being used for clinical

interpretation, saliency method heat maps are also used for the evaluation of CXR

interpretation models, for quality improvement (QI) and quality assurance (QA) in

clinical practices, and for dataset annotation[57]. Explainable AI is critical in high-stakes

contexts such as healthcare, and saliency methods have been used successfully to

develop and understand models generally. Indeed, we found that the saliency method

pipeline significantly outperformed the human benchmark on two pathologies when

using mIoU as an evaluation metric. However, our work also suggests that saliency

methods are not yet reliable enough to validate individual clinical decisions made by a

model. We found that saliency method localization performance, on balance, performed

worse than expert localization across multiple analyses and across many important

pathologies (our findings are consistent with recent work focused on localizing a single

pathology, Pneumothorax, in CXRs[58]). We hypothesize that this could be an algorithmic

artifact of saliency methods, whose relatively small heat maps (14x14 for Grad-CAM)

are interpolated to the original image dimensions (usually 2000x2000), resulting in

coarse resolutions. If used in clinical practice, heat maps that incorrectly highlight

medical images may exacerbate well-documented biases (chiefly, automation bias) and

erode trust in model predictions (even when model output is correct), limiting clinical

translation[22].

Since IoU computes the overlap of two segmentations but pointing game hit rate better

captures diagnostic attention, we suggest using both metrics when evaluating

localization performance in the context of medical imaging. While IoU is a commonly

used metric for evaluating semantic segmentation outputs, there are inherent limitations

to the metric in the pathological context. This is indicated by our finding that even the

human benchmark segmentations had low overlap with the ground-truth segmentations

(the highest expert mIoU was 0.720 for Cardiomegaly). One potential explanation for

this consistent underperformance is that pathologies can be hard to distinguish,

especially without clinical context. Furthermore, whereas many people might agree on

how to segment, say, a cat or a stop sign in traditional computer vision tasks,

radiologists use a certain amount of clinical discretion when defining the boundaries of a

pathology on a CXR. There can also be institutional and geographic differences in how

radiologists are taught to recognize pathologies, and studies have shown that there can

be high interobserver variability in the interpretation of CXRs[59–61]. We sought to address

this with the hit/miss evaluation metric, which highlights when two radiologists share the

same diagnostic intention, even if it is less exact than IoU in comparing segmentations

directly. The human benchmark localization using hit rate was above 0.9 for four

pathologies (Pneumothorax, Cardiomegaly, Enlarged Cardiomediastinum, and Support

Devices); these are pathologies for which there is often little disagreement between

radiologists about where the pathologies are located, even if the expert segmentations

are noisy. Further work is needed to demonstrate which segmentation evaluation

metrics, even beyond IoU and hit/miss, are more appropriate for certain pathologies and

downstream tasks when evaluating saliency methods for the clinical setting.

Our work builds upon several studies investigating the validity of saliency maps for

localization[62,63,64] and upon some early work on the trustworthiness of saliency methods

to explain DNNs in medical imaging[47]. However, as recent work has shown[32],

evaluating saliency methods is inherently difficult given that they are post-hoc

techniques. To illustrate this, consider the following models and saliency methods as

described by some oracle: (1) a model *M_bad* that has perfect AUROC for a given

image classification task, but that we know does *not* localize well (i.e. because the

model picks up on confounders in the image); (2) a model *M_good* that also has perfect

AUROC, but that we know *does* localize well (i.e. is looking at relevant regions of the

image); (3) a saliency method *S_bad* that does *not* properly reflect the model's

attention; and (4) a saliency method *S_good* that *does* properly reflect the model's

attention. Let us say that we are evaluating the following pipeline: we first classify an

image and we then apply a saliency method post hoc. Imagine that our evaluation

reveals poor localization performance as measured by mIoU or hit rate (as was the case

in our findings). There are three possible pipelines (combinations of model and saliency

method) that would lead to this scenario: (1) *M_bad* + *S_good*; (2) *M_good* + *S_bad*;

and (3) *M_bad* + *S_bad*. The first scenario (*M_bad* + *S_good*) is the one for which

saliency methods were originally intended: we have a working saliency method that

properly alerts us to models picking up on confounders. The second scenario (*M_good*

+ *S_bad*) is our nightmare scenario: we have a working model whose attention is

appropriately directed, but we reject it based on a poorly localizing saliency method.

Because all three scenarios result in poor localization performance, it is difficult—if not

impossible—to know whether poor localization performance is attributable to the model

or to the saliency method (or to both). While we cannot say whether models or saliency

methods are failing in the context of medical imaging, we can say that we should not

rely on saliency methods to evaluate model localization. Future work should explore

potential techniques for localization performance attribution.

There are several limitations of our work. First, we did not investigate the impact of

pathology prevalence in the training data on saliency method localization performance.

Second, some pathologies, such as effusions and cardiomegaly, are in similar locations

across frontal view CXRs, while others, such as lesions and opacities, can vary in

locations across CXRs. Future work could investigate how the location of pathologies

on a CXR in the training/test data distribution, and the consistency of those locations,

affect saliency method localization performance. Third, while we compared saliency

method-generated pixel-level segmentations to human expert pixel-level segmentations,

future work might explore how saliency method localization performance changes when

comparing bounding-box annotations, instead of pixel-level segmentations. Fourth, we

explored post-hoc interpretability methods given their prevalence in the context of

medical imaging, but we hope that by publicly releasing our development dataset of

pixel-level expert segmentations we can facilitate the development of models that make

use of ground-truth segmentations during training[57]. Fifth, the lack of a given finding can

in certain cases inform clinical diagnoses. A common example of this is the lack of

normal lung tissue pattern towards the edges of the thoracic cage, which is used to

detect pneumothorax. For any characteristic pattern, both the absence and the

presence provide diagnostic information to the radiologist. For example, the absence of

a pleural effusion pattern is also used to rule out pleural effusion. For any characteristic

radiological pattern, both the presence as well as the absence contribute to the final

radiology report. Future work can explore counterfactual visual explanations that are

similar to the counterfactual diagnostic process of a radiologist. Sixth, future work

should further explore the potentially confounding effect of model calibration on the

evaluation of saliency methods, especially when using segmentation, as opposed to

classification, models. Finally, the impact of saliency methods on the trust and efficacy

of users is underexplored.

In conclusion, we present a rigorous evaluation of a range of saliency methods and a

dataset of pixel-level expert segmentations, which can serve as a foundation for future

work exploring deep learning explainability techniques. This work is a reminder that care

should be taken when leveraging common saliency methods to validate individual

clinical decisions in deep learning-based workflows for medical imaging.

Methods

Ethical and information governance approvals.

A formal Stanford IRB review was conducted for the original collection of the CheXpert

dataset. The IRB waived the requirement to obtain informed consent as the data were

retrospectively collected and fully anonymized.

Dataset and clinical taxonomy. *Dataset description.* The localization experiments

were performed using CheXpert, a large public dataset for chest X-ray interpretation.

The CheXpert dataset contains 224,316 chest X-rays for 65,240 patients labeled for the

presence of 14 observations (13 pathologies and an observation of "No Finding") as

positive, negative, or uncertain. The CheXpert validation set consists of 234 chest X-

rays from 200 patients randomly sampled from the full dataset and was labeled

according to the consensus of three board-certified radiologists. The test set consists of

668 chest X-rays from 500 patients not included in the training or validation sets and

was labeled according to the consensus of five board-certified radiologists. See

Extended Data Fig. 10 for test set summary statistics. "Lung Opacity" in the CheXpert

dataset is the equivalent of "Airspace Opacity" in the CheXlocalize dataset.

Ground-truth segmentations. The chest X-rays in our validation set and test set were

manually segmented by two board-certified radiologists with 18 and 27 years of

experience, using the annotation software tool MD.ai[65] (see Supplementary Figs. S12

through S14). The radiologists were asked to contour the region of interest for all

observations in the chest X-rays for which there was a positive ground-truth label in the

CheXpert dataset. For a pathology with multiple instances, all the instances were

contoured. For Support Devices, radiologists were asked to contour any implanted or

invasive devices (including pacemakers, PICC/central catheters, chest tubes,

endotracheal tubes, feeding tubes and stents), and to ignore ECG lead wires or external

stickers visible in the chest X-ray.

Benchmark segmentations. To evaluate expert performance on the test set using IoU,

three radiologists, certified in Vietnam with 9, 10, and 18 years of experience, were

asked to segment the regions of interest for all observations in the chest X-rays for

which there was a positive ground-truth label in the CheXpert dataset. These

radiologists were also provided the same instructions for contouring as were provided to

the radiologists drawing the ground-truth segmentations. To extract the "maximally

activated" point from the benchmark segmentations, we asked the same radiologists to

locate each pathology present on each CXR using only a single most representative

point for that pathology on the CXR (see Supplementary Figs. S1 through S11 for the

detailed instructions given to the radiologists). There was no overlap between these

three radiologists and the two who drew the ground-truth segmentations.

Classification network architecture and training protocol. *Multi-label classification*

model. The model takes as input a single-view chest X-ray and outputs a probability for

each of the 14 observations. If more than one view is available, the model outputs the

maximum probability of the observations across the views. Each chest X-ray was

resized to 320x320 pixels and normalized before it was fed into the network. We used

the same image resolutions as CheXpert[36] and CheXNet[2], which demonstrated

radiologist-level performance on external test sets with 320x320 images. There are

models that are commercially deployed and have similar dimensions. For example, the

architecture used by medical AI software vendor Annalise.ai[66] is based on

EfficientNet[67], which takes input of 224x224. Chest X-rays were normalized prior to

being fed into the network by subtracting the mean of all images in the CheXpert

training set and then dividing by the standard deviation of all images in the CheXpert

training set. The model architectures DenseNet121, ResNet152, and Inception-v4 were

used. Cross-entropy loss was used to train the model. The Adam optimizer[68] was used

with default β-parameters of β1 = 0.9 and β2 = 0.999. The learning rate was tuned for

the different model architectures using grid search (over learning rates of 1e-3, 1e-4,

and 1e-5). The best learning rate for each architecture was: 1e-4 for DenseNet121, 1e-5

for ResNet152, and 1e-5 for Inceptionv4. Batches were sampled using a fixed batch

size of 16 images.

Ensembling. We use an ensemble of checkpoints to create both predictions and

saliency maps to maximize model performance. In order to capture uncertainties

inherent in radiograph interpretation, we train our models using four uncertainty

handling strategies outlined in CheXpert: Ignoring, Zeroes, Ones, and 3-Class

Classification. For each of the four uncertainty handling strategies, we train our model

three separate times, each time saving the 10 checkpoints across the three epochs with

the highest average AUC across 5 observations selected for their clinical importance

and prevalence in the validation set: Atelectasis, Cardiomegaly, Consolidation, Edema,

and Pleural Effusion. In total, after training, we have saved 4 x 30 = 120 checkpoints for

a given model. Then, from the 120 saved checkpoints for that model, we select the top

10 performing checkpoints for each pathology. For each CXR and each task, we

compute the predictions and saliency maps using the relevant checkpoints. We then

take the mean both of the predictions and of the saliency maps to create the final set of

predictions and saliency maps for the ensemble model. See Supplementary Table S1

for the performance of each model architecture (DenseNet121, ResNet152, and

Inception-v4) on each of the pathologies.

Evaluating localization performance. Saliency methods were used to visualize the

decision made by the classification network. Each saliency map was resized to the

original image dimension using bilinear interpolation. It was then normalized using min-

max normalization and converted into a binary segmentation using binary thresholding

(Otsu's method). For Occlusion, we used a window size of 40 and a stride of 40 for

each CXR.

Localization performance of each segmentation was evaluated using Intersection over

Union (IoU) score. The IoU is the ratio between the area of overlap and the area of

union between the ground-truth and the predicted segmentations, ranging from 0 to 1 (0

signifies no overlap and 1 signifies perfectly overlapping segmentations). We report the

mean Intersection over Union (mIoU) over 1,000 bootstrap replicates on the test set,

along with the 95% confidence intervals using the 2.5^{th} and 97.5^{th} percentiles of the

empirical distribution.

For the evaluation of DenseNet121+Integrated Gradients using IoU, we applied box

filtering of kernel size 100 to smooth the pixelated map. For the evaluation of

ResNet152+Integrated Gradients and of Inception-v4+Integrated Gradients using IoU,

we applied box filtering of kernel size 50. For the evaluation of DeepLIFT using IoU, we

applied box filtering of kernel size 50. For the evaluation of LRP using IoU, we applied

box filtering of kernel size 80. The kernel sizes were tuned on the validation set. The

noisy map is not a concern for hit rate because a single max pixel is extracted for the

entire image.

In Extended Data Fig. 1, we report mIoU localization performance using different

saliency map thresholding values. We first applied min-max normalizations to the

saliency maps so that each value gets transformed into a decimal between 0 and 1. We

then passed in a range of threshold values from 0.2 to 0.8 to create binary

segmentations and calculated the mIoU score per pathology under each threshold on

the validation set.

In Extended Data Fig. 2, we report the precision, recall/sensitivity, and specificity values

of the saliency method pipeline and the human benchmark segmentations on the test

set.

For this, we treat each pixel in the saliency method pipeline and the human

benchmark segmentations as a classification, use each pixel in the ground-

truth segmentation as the ground-truth label, and calculate precision, recall/sensitivity,

and specificity over all CXRs for each pathology. Precision is defined as the number of

total TP pixels / (number of total TP + FP pixels). Recall is defined as the number of

total TP pixels / (number of total TP + FN pixels). Specificity is defined as the number of

total TN pixels / (number of total TN + FP pixels).

In Extended Data Fig. 4, we report the saliency method pipeline test set localization

performance on the full dataset using mIoU. For this, we ensure that the final binary

segmentation is consistent with model probability output by applying another layer of

thresholding such that the segmentation mask produced all zeros if the predicted

probability was below a chosen level. The probability threshold is searched on the

interval of [0,0.8] with steps of 0.1. The exact value is determined per pathology by

maximizing the mIoU on the validation set.

In Extended Data Figs. 5 and 6, we report the percentage decrease from human

benchmark localization performance to saliency method pipeline localization

performance on the test set. To obtain the 95% confidence interval per pathology on the

percentage decrease from human benchmark localization performance to saliency

method pipeline localization performance, we first extracted the percentage decrease

statistic ([human benchmark mIoU or hit rate - saliency method pipeline mIoU or hit rate]

/ human benchmark mIoU or hit rate x 100) from each of the 1,000 human benchmark

and the 1,000 saliency method pipeline mIoU/hit rate bootstrap replicates for each

pathology. In doing so, we created the bootstrap distribution of the percentage decrease

statistic. We reported the 95% CI using the 2.5^{th} and 97.5^{th} percentiles of the empirical

distribution. To obtain the 95% CI on the average percentage decrease over all

pathologies, the methodology is the same: we created bootstrap replicates of the

average human benchmark and saliency method pipeline mIoUs/hit rates over all

pathologies, extracted the percentage decrease statistic from each replicate, and then

reported the 95% CI using the 2.5^{th} and 97.5^{th} percentiles of the empirical distribution.

Statistical analyses.

Pathology Characteristics. The pathology characteristics used in all regressions were

calculated on the ground-truth annotations. The four characteristics are defined as

follows: (1) Number of instances is the number of separate segmentations drawn by the

radiologist for a given pathology. (2) Size is the area of the pathology divided by the

total image area. (3) and (4) Elongation and irrectangularity are geometric features that

measure shape complexities. They were designed to quantify what radiologists

qualitatively describe as focal or diffused. To calculate the metrics, a rectangle of

minimum area enclosing the contour is fitted to each pathology. Elongation is defined as

the ratio of the rectangle's longer side to shorter side. Irrectangularity = 1 - (area of

segmentation/area of enclosing rectangle), with values ranging from 0 to 1 (1 being very

irrectangular). When there were multiple instances within one pathology, we used the

characteristics of the dominant instance (largest in perimeter). All geometric features

are normalized using min-max normalization per-pathology before aggregation so that

they are comparable on scales of magnitudes.

Model Confidence. We used the probability output of the DNN architecture for model

confidence. The probabilities were on the similar scale of 0-1 and we did not apply min-

max normalization. We report the 95% confidence interval and p-value of the regression

coefficients using Student's t-distribution.

For the statistical analyses on the *full* dataset to determine whether there was any

correlation between the model's confidence in its prediction and saliency method

pipeline performance using IoU (Table 3), we ensure that the final binary segmentation

is consistent with model probability output by applying another layer of thresholding

such that the segmentation mask produced all zeros if the predicted probability was

below a chosen level. The probability threshold is searched on the interval of [0,0.8] with

steps of 0.1. The exact value is determined per pathology by maximizing the mIoU on

the validation set.

For the statistical analyses to determine whether there was any correlation between the

model's confidence in its prediction and saliency method pipeline performance using

hit/miss (Extended Data Fig. 9), we used the true positive slice of the dataset (CXRs

with both the most representative point identified by the saliency method/human

benchmark and also the ground-truth segmentations). Since every heat map contains a

maximally activated point (the pixel with the highest value) regardless of model

probability output, using the full dataset has limited value since false positives are due

to metric set up and are not associated with model probability.

Data Availability

The CheXlocalize dataset is available here:

https://stanfordaimi.azurewebsites.net/datasets/abfb76e5-70d5-4315-badc-

c94dd82e3d6d. The CheXpert dataset is available here

https://stanfordmlgroup.github.io/competitions/chexpert/.

Code Availability

The code used to produce our results is available in the following public repository

under the MIT License: https://github.com/rajpurkarlab/cheXlocalize.

Acknowledgements

We would like to acknowledge MD.ai for generously providing us access to their annotation platform. We would like to acknowledge Weights & Biases for generously providing us access to their experiment tracking tools.

Author Contributions

Conceptualization: P.R. and A.P. Design: P.R., A.P., A.S., X.G. and A.A. Data analysis and interpretation: A.S., X.G., A.A., P.R., A.P., S.T., C.N., V.N., J.S., and F.B. Drafting of the manuscript: A.S., X.G., A.A., and P.R. Critical revision of the manuscript for important intellectual content: A.P, S.T., C.N., V.N., J.S., F.B, A.N., and M.L. Supervision: A.N., M.L., and P.R. Research was primarily performed while A.S. was at Stanford University. M.L. and P.R. contributed equally.

Competing Interests

M.L. is an advisor for and/or has research funded by GE, Philips, Carestream, Nines Radiology, Segmed, Centaur Labs, Microsoft, BunkerHill, and Amazon Web Services (none of the funded research was relevant to this project). A.P. is a medical associate at Cerebriu. The remaining authors declare no competing interests.

References

1. Rajpurkar, P. *et al.* Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists. *PLOS Med.* **15**, e1002686 (2018).

2. Rajpurkar, P. *et al.* CheXNet: Radiologist-Level Pneumonia Detection on Chest X-

Rays with Deep Learning. *ArXiv171105225 Cs Stat* (2017).

3. Bien, N. *et al.* Deep-learning-assisted diagnosis for knee magnetic resonance

imaging: Development and retrospective validation of MRNet. *PLOS Med.* **15**,

e1002699 (2018).

4. Baselli, G., Codari, M. & Sardanelli, F. Opening the black box of machine learning in

radiology: can the proximity of annotated cases be a way? *Eur. Radiol. Exp.* **4**, 30

(2020).

5. Litjens, G. *et al.* A survey on deep learning in medical image analysis. *Med. Image*

Anal. **42**, 60–88 (2017).

6. Wang, F., Kaushal, R. & Khullar, D. Should Health Care Demand Interpretable

Artificial Intelligence or Accept "Black Box" Medicine? *Ann. Intern. Med.* **172**, 59–60

(2019).

7. Goodman, B. & Flaxman, S. European Union regulations on algorithmic decision-

making and a 'right to explanation'. *AI Mag.* **38**, 50–57 (2017).

8. Venugopal, V. K., Takhar, R., Gupta, S., Saboo, A. & Mahajan, V. *Clinical*

Explainability Failure (CEF) & Explainability Failure Ratio (EFR) – changing the way

we validate classification algorithms? J Med Syst **46**, 20 (2022).

9. Pasa, F., Golkov, V., Pfeiffer, F., Cremers, D. & Pfeiffer, D. Efficient Deep Network

Architectures for Fast Chest X-Ray Tuberculosis Screening and Visualization. *Sci.*

Rep. **9**, 6268 (2019).

10. Simonyan, K., Vedaldi, A. & Zisserman, A. Deep Inside Convolutional Networks:

Visualising Image Classification Models and Saliency Maps. *ArXiv13126034 Cs*

(2014).

11. Aggarwal, M. *et al.* Towards Trainable Saliency Maps in Medical Imaging.

ArXiv201107482 Cs Eess (2020).

12. Tjoa, E. & Guan, C. Quantifying Explainability of Saliency Methods in Deep

Neural Networks. *ArXiv200902899 Cs* (2020).

13. Badgeley, M. A. *et al.* Deep learning predicts hip fracture using confounding

patient and healthcare variables. *Npj Digit. Med.* **2**, 31 (2019).

14. Zech, J. R. *et al.* Variable generalization performance of a deep learning model

to detect pneumonia in chest radiographs: A cross-sectional study. *PLOS Med.* **15**,

e1002683 (2018).

15. DeGrave, A. J., Janizek, J. D. & Lee, S.-I. AI for radiographic COVID-19

detection selects shortcuts over signal. Nat Mach Intell **3**, 610-619 (2021).

16. Makimoto, H. *et al.* Performance of a convolutional neural network derived from

an ECG database in recognizing myocardial infarction. *Sci. Rep.* **10**, 8445 (2020).

17. Porumb, M., Stranges, S., Pescapè, A. & Pecchia, L. Precision Medicine and

Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events

Detection based on ECG. *Sci. Rep.* **10**, 1–16 (2020).

18. Tham, Y.-C. *et al.* Referral for disease-related visual impairment using retinal

photograph-based deep learning: a proof-of-concept, model development study.

Lancet Digit. Health **3**, e29–e40 (2021).

19.   Varadarajan, A. V. *et al.* Deep Learning for Predicting Refractive Error From

Retinal Fundus Images. *Invest. Ophthalmol. Vis. Sci.* **59**, 2861–2868 (2018).

20.   Mitani, A. *et al.* Detection of anaemia from retinal fundus images via deep

learning. *Nat. Biomed. Eng.* **4**, 18–27 (2020).

21.   Deep Learning to Assess Long-term Mortality From Chest Radiographs |

Pulmonary Medicine | JAMA Network Open | JAMA Network. https://jamanetwork-

com.stanford.idm.oclc.org/journals/jamanetworkopen/fullarticle/2738349.

22.   Rajpurkar, P. *et al.* CheXaid: deep learning assistance for physician diagnosis of

tuberculosis using chest x-rays in patients with HIV. *Npj Digit. Med.* **3**, 1–8 (2020).

23.   Rajpurkar, P. *et al.* AppendiXNet: Deep Learning for Diagnosis of Appendicitis

from A Small Dataset of CT Exams Using Video Pretraining. *Sci. Rep.* **10**, 3958

(2020).

24.   Huang, S.-C. *et al.* PENet—a scalable deep-learning model for automated

diagnosis of pulmonary embolism using volumetric CT imaging. *Npj Digit. Med.* **3**, 1–

9 (2020).

25.   Rudin, C. Stop explaining black box machine learning models for high stakes

decisions and use interpretable models instead. *Nat. Mach. Intell.* **1**, 206–215 (2019).

26.   Eitel, F. & Ritter, K. Testing the Robustness of Attribution Methods for

Convolutional Neural Networks in MRI-Based Alzheimer's Disease Classification.

Interpretability of Machine Intelligence in Medical Image Computing and Multimodal

Learning for Clinical Decision Support (eds. Suzuki, K. et al.) 3-11 (Springer

International Publishing, 2019). doi:10.1007/978-3-030-33850-3_1.

27.   Young, K., Booth, G., Simpson, B., Dutton, R. & Shrapnel, S. Deep Neural

Network or Dermatologist? in *Interpretability of Machine Intelligence in Medical Image*

Computing and Multimodal Learning for Clinical Decision Support (eds. Suzuki, K. et

al.) 48–55 (Springer International Publishing, 2019). doi:10.1007/978-3-030-33850-

3_6.

28.   Ghassemi, M., Oakden-Rayner, L. & Beam, A. L. The false hope of current

approaches to explainable artificial intelligence in health care. Lancet Digit. Health 3,

e745–e750 (2021).

29.   Reyes, M. *et al.* On the Interpretability of Artificial Intelligence in Radiology:

Challenges and Opportunities. Radiol. Artif. Intell. **2**, e190043 (2020).

30.   Selvaraju, R. R. *et al.* Grad-CAM: Visual Explanations from Deep Networks via

Gradient-based Localization. *Int. J. Comput. Vis.* **128**, 336–359 (2020).

31.   Chattopadhay, A., Sarkar, A., Howlader, P. & Balasubramanian, V. N. Grad-

CAM++: Generalized Gradient-Based Visual Explanations for Deep Convolutional

Networks. in *2018 IEEE Winter Conference on Applications of Computer Vision*

(WACV) 839–847 (2018). doi:10.1109/WACV.2018.00097.

32.   Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. in

Proceedings of the 34th International Conference on Machine Learning - Volume 70

3319–3328 (JMLR.org, 2017).

33.   Huang, G., Liu, Z., Van Der Maaten, L. & Weinberger, K. Q. Densely Connected

Convolutional Networks. in *2017 IEEE Conference on Computer Vision and Pattern*

Recognition (CVPR) 2261–2269 (IEEE, 2017). doi:10.1109/CVPR.2017.243.

34.   He, K., Zhang, X., Ren, S. & Sun, J. Deep Residual Learning for Image

Recognition. in *2016 IEEE Conference on Computer Vision and Pattern Recognition*

(CVPR) 770–778 (IEEE, 2016). doi:10.1109/CVPR.2016.90.

35.   Szegedy, C. *et al.* Going deeper with convolutions. in *2015 IEEE Conference on*

Computer Vision and Pattern Recognition (CVPR) 1–9 (2015).

doi:10.1109/CVPR.2015.7298594.

36.   Irvin, J. *et al.* CheXpert: A Large Chest Radiograph Dataset with Uncertainty

Labels and Expert Comparison. *Proc. AAAI Conf. Artif. Intell.* **33**, 590–597 (2019).

37.   Otsu, N. A Threshold Selection Method from Gray-Level Histograms. *IEEE Trans*

Syst. Man Cybern. 62–66 (1979).

38.   Zhang, J. *et al.* Top-down Neural Attention by Excitation Backprop. *Int. J.*

Comput. Vis. **126,** *1084-1102 (2018).*

39.   Kim, H.-E. *et al.* Changes in cancer detection and false-positive recall in

mammography using artificial intelligence: a retrospective, multireader study. *Lancet*

Digit. Health **2**, e138–e148 (2020).

40.   Efron, B. & Tibshirani, R. J. *An Introduction to the Bootstrap.* (CRC Press, 1994).

41.   Bany Muhammad, M. *et al.* Eigen-CAM: Visual Explanations for Deep

Convolutional Neural Networks. *SN COMPUT. SCI.* **2,** 47 (2021).

42.   Shrikumar, A., Greenside, P. & Kundaje, A. Learning Important Features

Through Propagating Activation Differences. In *International conference on machine*

learning 3145-3153 (PMLR, 2017).

43.   Bach, S. et al. On Pixel-Wise Explanations for Non-Linear Classifier Decisions by

Layer-Wise Relevance Propagation. PLOS ONE 10, e0130140 (2015).

44.   Zeiler, M. D. & Fergus, R. Visualizing and Understanding Convolutional

Networks. in *Computer Vision – ECCV 2014* (eds. Fleet, D., Pajdla, T., Schiele, B. &

Tuytelaars, T.) 818–833 (Springer International Publishing, 2014). doi:10.1007/978-3-

319-10590-1_53.

45.   Vrabac, D. *et al.* DLBCL-Morph: Morphological features computed using deep

learning for an annotated digital DLBCL image set. *Sci Data* **8,** 135 (2021).

46.   Ayhan, M. S. et al. Clinical validation of saliency maps for understanding deep

neural networks in ophthalmology. Med. Image Anal. 77, 102364 (2022).

47.   Arun, N. et al. Assessing the Trustworthiness of Saliency Maps for Localizing

Abnormalities in Medical Imaging. Radiol. Artif. Intell. 3, e200267 (2021).

48.   Wang, X. *et al.* ChestX-ray8: Hospital-Scale Chest X-Ray Database and

Benchmarks on Weakly-Supervised Classification and Localization of Common

Thorax Diseases. in *2017 IEEE Conference on Computer Vision and Pattern*

Recognition (CVPR) 2097–2106 (IEEE, 2017).

49. Nguyen, H. Q. *et al.* VinDr-CXR: An open dataset of chest X-rays with radiologist's

annotations. (2022) doi:10.48550/arXiv.2012.15029.

50.   SIIM-ACR Pneumothorax Segmentation. https://kaggle.com/c/siim-acr-

pneumothorax-segmentation.

51.   Steiner, D. F. *et al.* Impact of Deep Learning Assistance on the Histopathologic

Review of Lymph Nodes for Metastatic Breast Cancer. *Am. J. Surg. Pathol.* **42**,

1636–1646 (2018).

52.   Uyumazturk, B. *et al.* Deep Learning for the Digital Pathologic Diagnosis of

849   Cholangiocarcinoma and Hepatocellular Carcinoma: Evaluating the Impact of a Web-

850   based Diagnostic Assistant. *ArXiv191107372 Eess* (2019).

851   53.   Park, A. *et al.* Deep Learning–Assisted Diagnosis of Cerebral Aneurysms Using

852   the HeadXNet Model. *JAMA Netw. Open* **2**, e195600 (2019).

853   54.   Annalise.ai - Medical imaging AI, by clinicians for clinicians. *Annalise.ai*

854   https://annalise.ai/.

855   55.   Lunit Inc. https://www.lunit.io/en.

856   56.   Qure.ai | Artificial Intelligence for Radiology. https://qure.ai/.

857   57.   Gadgil, S., Endo, M., Wen, E., Ng, A. Y. & Rajpurkar, P. CheXseg: Combining

858   Expert Annotations with DNN-generated Saliency Maps for X-ray Segmentation. In

859   *Proceedings of the Fourth Conference on Medical Imaging with Deep Learning* 190-

860   204 (PMLR, 2021).

861   58.   Crosby, J., Chen, S., Li, F., MacMahon, H. & Giger, M. Network output

862   visualization to uncover limitations of deep learning detection of pneumothorax. in

863   *Medical Imaging 2020: Image Perception, Observer Performance, and Technology*

864   *Assessment* vol. 11316 113160O (International Society for Optics and Photonics,

865   2020).

866   59.   Melbye, H. & Dale, K. Interobserver Variability in the Radiographic Diagnosis of

867   Adult Outpatient Pneumonia. *Acta Radiol.* **33**, 79–81 (1992).

868   60.   Herman, P. G. *et al.* Disagreements in Chest Roentgen Interpretation. *CHEST*

869   **68**, 278–282 (1975).

61.   Albaum, M. N. *et al.* Interobserver Reliability of the Chest Radiograph in

Community-Acquired Pneumonia. *CHEST* **110**, 343–350 (1996).

62.   Arun, N. T. *et al.* Assessing the validity of saliency maps for abnormality

localization in medical imaging. In *Medical Imaging with Deep Learning.* (2020).

63.   Graziani, M., Lompech, T., Müller, H. & Andrearczyk, V. *Evaluation and*

Comparison of CNN Visual Explanations for Histopathology. (2020).

64.   Choe, J. et al. Evaluating Weakly Supervised Object Localization Methods Right.

In *Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern*

Recognition 3133-3142 (IEEE, 2020).

65.   MD.ai. https://www.md.ai/.

66.   Seah, J. C. Y. et al. Effect of a comprehensive deep-learning model on the

accuracy of chest x-ray interpretation by radiologists: a retrospective, multireader

multicase study. Lancet Digit. Health 3, e496–e506 (2021).

67.   Tan, M. & Le, Q. V. EfficientNet: Rethinking Model Scaling for Convolutional

Neural Networks. In *International conference on machine learning 6105-6114* (PMLR,

2020).

68   Kingma, D. P. & Ba, J. Adam: A Method for Stochastic Optimization.

ArXiv14126980 Cs (2017).

Extended Data

Extended Data Fig. 1 | mIoU localization performance of the saliency method pipeline on the test set using threshold values tuned on the validation set. a, We first applied min-max normalizations to the Grad-CAM saliency maps so that each value gets transformed into a decimal between 0 and 1. We then passed in a range of threshold values from 0.2 to 0.8 to create binary segmentations and plotted the mIoU score per pathology under each threshold on the validation set. The threshold that gives the max mIoU for each pathology is marked with an "X". Pathologies are sorted alphabetically and shown in two plots for readability. **b**, Comparing mIoU localization performances of the saliency method pipeline on the test set (using the best thresholds tuned on the validation set) and the human benchmark. We found that the saliency method pipeline outperformed the human benchmark on two pathologies and underperformed the human benchmark on five pathologies. For the remaining three pathologies, the performance differences were not statistically significant. This finding is consistent with what we report in the manuscript using Otsu's method.

pathology	precision		recall/sensitivity		specificity	
	saliency method pipeline	human benchmark	saliency method pipeline	human benchmark	saliency method pipeline	human benchmark
Airspace Opacity	0.194	**0.526**	**0.638**	0.328	0.838	**0.982**
Atelectasis	0.119	**0.838**	**0.593**	0.111	0.852	**0.999**
Cardiomegaly	0.277	**0.947**	0.621	**0.728**	0.911	**0.998**
Consolidation	0.045	**0.701**	**0.639**	0.158	0.915	**1.000**
Edema	0.114	**0.753**	**0.652**	0.330	0.848	**0.997**
Enlarged Cardiom.	0.454	**0.905**	0.467	**0.622**	0.931	**0.992**
Lung Lesion	0.003	**0.614**	**0.797**	0.469	0.887	**1.000**
Pleural Effusion	0.052	**0.653**	**0.673**	0.154	0.806	**0.999**
Pneumothorax	0.005	**0.838**	**0.786**	0.459	0.866	**1.000**
Support Devices	0.120	**0.849**	**0.510**	0.425	0.860	**0.997**

Extended Data Fig. 2 | Precision, recall/sensitivity, and specificity values of the saliency method pipeline and the human benchmark segmentations on the test set. We treated each pixel in the saliency method pipeline and the human benchmark segmentations as a classification, used each pixel in the ground-truth segmentation as the ground-truth label, and calculated the precision, recall/sensitivity, and specificity over all CXRs for each pathology. For each pathology and each metric, we highlight the higher of the two (saliency method pipeline or human benchmark) in **bold**.

pathology	Grad-CAM			Grad-CAM++			Integrated Gradients		
	DenseNet121	ResNet152	Inception-v4	DenseNet121	ResNet152	Inception-v4	DenseNet121	ResNet152	Inception-v4
mIoU									
Airspace Opacity	**0.248**	0.194	0.090	**0.234**	0.198	0.115	**0.123**	0.119	0.052
Atelectasis	**0.254**	0.221	0.115	**0.245**	0.210	0.106	**0.116**	0.115	0.064
Cardiomegaly	**0.452**	0.424	0.120	**0.346**	0.257	0.196	**0.160**	0.154	0.089
Consolidation	**0.408**	0.334	0.079	**0.296**	0.245	0.130	**0.177**	0.112	0.069
Edema	**0.362**	0.240	0.203	**0.388**	0.345	0.266	0.073	0.062	**0.099**
Enlarged Cardiom.	**0.379**	0.272	0.065	**0.400**	0.382	0.295	**0.154**	0.152	0.094
Lung Lesion	**0.101**	0.066	0.003	**0.089**	0.069	0.045	**0.107**	0.063	0.001
Pleural Effusion	**0.235**	0.204	0.120	**0.195**	0.176	0.090	0.088	**0.091**	0.067
Pneumothorax	**0.213**	0.171	0.088	**0.216**	0.184	0.124	0.077	0.070	**0.078**
Support Devices	**0.163**	0.147	0.116	**0.133**	0.126	0.099	**0.099**	0.074	0.066
hit rate									
Airspace Opacity	**0.498**	0.428	0.106	**0.558**	0.522	0.148	**0.606**	0.586	0.122
Atelectasis	**0.501**	0.490	0.062	**0.621**	**0.621**	0.118	**0.520**	0.453	0.187
Cardiomegaly	0.903	**0.915**	0.126	**0.732**	0.297	0.493	0.697	**0.748**	0.268
Consolidation	0.738	**0.797**	0.030	**0.708**	0.600	0.284	**0.624**	0.538	0.115
Edema	**0.746**	0.432	0.385	**0.781**	0.745	0.457	0.300	**0.350**	0.180
Enlarged Cardiom.	**0.818**	0.627	0.030	0.630	0.631	**0.731**	0.704	**0.730**	0.205
Lung Lesion	**0.290**	0.146	0.000	**0.290**	0.146	0.000	**0.423**	0.211	0.000
Pleural Effusion	**0.507**	0.499	0.133	0.347	**0.473**	0.107	0.332	**0.400**	0.182
Pneumothorax	0.392	**0.600**	0.000	0.489	**0.698**	0.097	**0.801**	0.498	0.097
Support Devices	**0.355**	0.287	0.133	**0.364**	0.334	0.150	**0.491**	0.442	0.324

Extended Data Fig. 3 | Test set localization performance for each combination of saliency method and CNN architecture. For each pathology and saliency method, we highlight the highest performing CNN architecture in **bold**.

921
Extended Data Fig. 4 | Saliency method pipeline test set localization performance
on the full dataset using mIoU. True negatives (CXRs whose ground-truth label is
negative for a given pathology and for which there were neither human benchmark nor
saliency method pipeline segmentations for that pathology) were excluded from the
metric calculation. To control for false positives, we ensure that the final binary
segmentation is consistent with model probability output by applying another layer of
thresholding such that the segmentation mask produced all zeros if the predicted
probability was below a chosen level. The probability threshold is searched on the
interval of [0,0.8] with steps of 0.1. The exact value is determined per pathology by
maximizing the mIoU on the validation set. We found that on the full dataset, for seven
of the 10 pathologies, the saliency method pipeline had a significantly lower mIoU than
the human benchmark.
934

pathology	human benchmark mIoU	saliency method pipeline mIoU	% decrease (95% CI)
Lung Lesion	0.426	0.101	76.2 (59.1, 87.5)
Support Devices	0.444	0.163	63.3 (60.8, 65.8)
Pneumothorax	0.435	0.213	50.9 (14.6, 69.5)
Cardiomegaly	0.720	0.452	37.2 (34.0, 40.4)
Enlarged Cardiom.	0.569	0.379	33.4 (29.0, 37.4)
Airspace Opacity	0.260	0.248	4.8 (-6.1, 14.6)
Pleural Effusion	0.219	0.235	-7.6 (-34.5, 13.3)
Edema	0.335	0.362	-7.9 (-19.7, 2.6)
Atelectasis	0.124	0.254	-104.4 (-134.2, -78.2)
Consolidation	0.179	0.408	-128.1 (-226.8, -74.5)
Average	0.371	0.282	24.0 (18.2, 29.6)

Extended Data Fig. 5 | Percentage decrease from human benchmark mIoU to saliency method pipeline mIoU on the test set. Pathologies are sorted first by statistical significance of percentage decrease from human benchmark mIoU to saliency method pipeline mIoU (high to low), and then by percentage decrease from human benchmark mIoU to saliency method pipeline mIoU (high to low). We use 95% bootstrap confidence interval.

pathology	human benchmark hit rate (%)	saliency method pipeline hit rate (%)	% decrease (95% CI)
Lung Lesion	0.850	0.290	65.9 (35.3, 91.7)
Support Devices	0.933	0.355	61.9 (56.2, 67.5)
Pneumothorax	1.000	0.392	60.8 (27.3, 92.3)
Atelectasis	0.870	0.501	42.4 (33.1, 51.0)
Pleural Effusion	0.718	0.507	29.4 (14.3, 42.5)
Enlarged Cardiom.	0.957	0.818	14.5 (9.6, 19.2)
Cardiomegaly	0.972	0.903	7.1 (2.1, 11.8)
Airspace Opacity	0.559	0.498	10.9 (-2.0, 23.1)
Edema	0.769	0.746	3.0 (-13.2, 18.5)
Consolidation	0.510	0.738	-44.7 (-130.0, 0.0)
Average	0.814	0.575	29.4 (23.1, 35.5)

943
Extended Data Fig. 6 | Percentage decrease from human benchmark hit rate to
saliency method pipeline hit rate on the test set. Pathologies are sorted first by
statistical significance of percentage decrease from human benchmark hit rate to
saliency method pipeline hit rate (high to low), and then by percentage decrease from
human benchmark hit rate to saliency method pipeline hit rate (high to low). We use
95% bootstrap confidence interval.
950

pathology	ensemble model	single checkpoint
mIoU		
Airspace Opacity	**0.248**	0.241
Atelectasis	**0.254**	0.233
Cardiomegaly	**0.452**	0.419
Consolidation	**0.408**	0.369
Edema	**0.362**	0.360
Enlarged Cardiom.	<u>0.379</u>	0.297
Lung Lesion	**0.101**	0.099
Pleural Effusion	**0.235**	0.205
Pneumothorax	**0.213**	0.181
Support Devices	**0.163**	0.150
hit rate		
Airspace Opacity	0.498	**0.534**
Atelectasis	0.501	**0.504**
Cardiomegaly	**0.903**	0.846
Consolidation	**0.738**	0.711
Edema	0.746	**0.749**
Enlarged Cardiom.	<u>0.818</u>	0.704
Lung Lesion	**0.290**	0.286
Pleural Effusion	**0.507**	0.390
Pneumothorax	0.392	**0.491**
Support Devices	**0.355**	0.312

Extended Data Fig. 7 | Test set saliency method pipeline localization performance using an ensemble model vs. using the top performing single checkpoint for each pathology. For each pathology, we highlight in **bold** the model (ensemble or single checkpoint) that has the higher metric, and we <u>underline</u> it if the difference is statistically significant (using 95% bootstrap confidence interval).

**Extended Data Fig. 8 | Test set distribution of four geometric features across all
10 pathologies.** The black horizontal line in each box indicates the median feature
value for that pathology, and each successive level outward contains half of the
remaining data. The height of the box indicates the range of feature values in the
quantile.

pathology	CXRs including all positives and false negatives (*n*)	Linear regression coefficient	Spearman correlation coefficient
Airspace Opacity	309	1.080 (0.707, 1.453) ***	0.284 (0.178, 0.383) ***
Atelectasis	177	0.481 (-0.086, 1.047)	0.076 (-0.072, 0.221)
Cardiomegaly	175	0.206 (0.006, 0.406) *	0.185 (0.038, 0.324) *
Consolidation	35	1.219 (-0.204, 2.642)	0.324 (-0.011, 0.593)
Edema	83	0.259 (-0.226, 0.745)	0.168 (-0.050, 0.370)
Enlarged Cardiom.	297	0.667 (-0.153, 1.487)	0.191 (0.078, 0.298) ***
Lung Lesion	14	0.657 (-0.825, 2.139)	0.392 (-0.175, 0.764)
Pleural Effusion	120	1.009 (0.533, 1.485) ***	0.347 (0.179, 0.496) ***
Pneumothorax	10	0.342 (-1.549, 2.233)	0.142 (-0.535, 0.708)
Support Devices	314	0.119 (-0.120, 0.358)	0.102 (-0.009, 0.210)
All pathologies	1534	-0.319 (-0.399, -0.239) ***	-0.186 (-0.234, -0.138) ***

* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001

965
Extended Data Fig. 9 | Hit/miss: Coefficients from regressions on model
assurance. Statistical analysis to determine whether there was any correlation between
the model's confidence in its prediction and saliency method pipeline performance using
hit/miss. We used the true positive slice of the dataset (CXRs with both the most
representative point identified by the saliency method/human benchmark and also the
ground-truth segmentations). Since every heat map contains a maximally activated
point (the pixel with the highest value) regardless of model probability output, using the
full dataset has limited value since false positives are due to metric set up and are not
associated with model probability.
975

sample size	
Number studies	500
Number CXRs	668
pathology	**CXRs (*n*)**
Airspace Opacity	309
Atelectasis	177
Cardiomegaly	175
Consolidation	35
Edema	83
Enlarged Cardiom.	297
Lung Lesion	14
Pleural Effusion	120
Pneumothorax	10
Support Devices	314
No pathology identified	169

976
977 **Extended Data Fig. 10 | Test set summary statistics.**